ECCO 2019 European Cancer Summit Webcasts
European Cancer Care: Across Borders
Webcasts from the ECCO 2019 European Cancer Summit:
Moderated by ECCO 2019 Summit Co-Chairs: Prof Philip Poortmans, President of the European Cancer Organisation and Dr Ian Banks, Board Member of the European Cancer Organisation and Chair of the Patient Advisory Committee.
The opening session featured a report back on elements of progress made in respect to the themes and issues given attention at the ECCO 2018 European Cancer Summit.
Please click on the video thumbnail to view the related webcast.
Moderated by Professor Mark Lawler, Queen’s University Belfast & Vice President of the European Cancer Concord, and Gilliosa Spurrier-Bernard, Patient Advisory Committee of the European Cancer Organisation & Melanoma Patient Network Europe.
The session examined, variously, EU mission activity on cancer, sector and tumour specific targets for improvement, and the goal orientated approaches employed by the member societies of the European Cancer Organisation and patient associations.
Please click on the video thumbnail to view the related webcast.
Moderated by Prof Daniel Kelly, Board Member of the European Cancer Organisation, Past President of EONS.
The goal of eliminating HPV related cancers is a mercifully obtainable one, but requires a truly multi-stakeholder and multidisciplinary effort to achieve.
Co-led with the European Society of Gynaecological Oncology (ESGO), the session will investigate such matters as gender neutral vaccination, the economic evidence for prevention actions, and relevant and recent EU and national experiences in respect to combatting limiting factors such as the spread of ‘fake news’ about vaccination.
Please click on the video thumbnail to view the related webcast.
Moderated by Jan Geisler, CML Advocates Network and Patient Advisory Committee of the European Cancer Organisation.
No significant EU legislative initiative has been taken to improve the access to clinical trials for patients living in another EU country. With this in mind, in a collaborative effort, a team comprised of researchers from the European Forum for Good Clinical Practice (EFGCP), the European Organisation for Research and Treatment of Cancer (EORTC), KU Leuven and Patvocates, with the support of the European Federation of Pharmaceutical Industries and Associations (EFPIA), engaged in an exploratory study on this topic.
Please click on the video thumbnail to view the related webcast.
Moderated by Prof Regina Beets-Tan, Board Member of the European Cancer Organisation and 2nd Vice-President of the European Society of Radiology (ESR) and Sema Erdam, Europa Donna.
The Summit session on AI, led by the European Society of Radiology (ESR), examined the ways in which AI is already impacting cancer care; what can be expected in the future in respect to AI’s impact on cancer care; and, how regulatory, commercial, governmental, healthcare professional and patient stakeholders are responding to AI trends in cancer care.
Please click on the video thumbnail to view the related webcast.
Dr Andriukaitis reflected on the achievements of the 2014-2019 European Commission mandate in respect to aiding countries in combating cancer and assisting patients to receive optimal care and treatment.
Report: Spending on cancer prevention is ‘a drop in the ocean’, says Andriukaitis
Please click on the video thumbnail to view the related webcast.
Moderated by Prof Ruth Ladenstein, project coordinator of the European Reference Network (ERN) for paediatric cancer, ERN PaedCan and Anita Kienesberger, Childhood Cancer International (CCI).
The session opened with an overview by Hélène le Borgne and Caroline Hager from the Directorate-General for Health and Food Safety of the European Commission. The presentation covered the background to the Directive on the application of patient rights in Cross-Border Healthcare and the European Reference Networks concept, progress in their implementation so far and the working challenges to their operations presently being overcome.
Please click on the video thumbnail to view the related webcast.
Moderated by Teodora Kolarova, Patient Advisory Committee of the European Cancer Organisation and International Neuroendocrine Cancer Alliance (INCA) and Maria Krini, The Cyprus Association of Cancer Patients and Friends ( PASYKAF).
Led by the European Cancer Leagues (ECL), this session will pick up on the recommendations and research of the ECL Access to Medicines Taskforce, which has brought attention to the disparities in availability of cancer treatments across Europe, some of the variety of factors underlying this, and potential mechanisms for European cooperation that may achieve improvement.
Please click on the video thumbnail to view the related webcast.
Moderated by Dr Denis Lacombe, Director of the European Organisation for Research and Treatment of Cancer (EORTC) and Roger Wilson, sarcoma survivor and patient advocate.
Building on the EORTC ‘Manifesto for a new approach for better medicine in Europe’ and recently published proposals for reforming the model for late translational research, the session reflected on the role of data in driving change and improvement in research, and the remaining obstacles to more meaningful exchange between systems in this area.
Finally, the session will also consider how models of clinical research in cancer in Europe can better involve the expertise and contributions of all healthcare professionals and the patient community.
Please click on the video thumbnail to view the related webcast.
Dr Polite has been invited to share approaches by ASCO in the United States to issues and topic in focus at the European Cancer Summit, including in respect to improving quality of cancer care and ensuring better equity of access to treatment.
Please click on the video thumbnail to view the related webcast.
Moderated by Emma Woodford, Chief Operating Officer of the European Oncology Nursing Society (EONS) and Anne-Marie Baird, ECCO Patient Advisory Committee and Lung Cancer Europe (LuCE).
Key matters addressed during the session included:
- The history of professional specialisation in cancer care, and benefits achieved
- Factors driving oncology workforce specialisation in the present era, including scientific development, complexity of care, and new opportunities for professional development
- Case studies of specialisation in cancer care
- Challenges to achieving specialisation, including:
o Fragmentation in approaches across countries
o National and EU level regulatory barriers and difficulties - Opportunities to further achieving and embedding specialisation in cancer care
- Recommendations and conclusions to be carried forward for the European Commission term 2019-2024
Please click on the video thumbnail to view the related webcast.
Moderated by Prof Peter Schirmacher, European Society of Pathology (ESP) and Dr Matti Aapro, ECCO President-Elect and Board Member of the European School of Oncology (ESO).
Co-led by ECCO member European Society of Pathology (ESP), this session delved into such questions as:
- In what ways is molecular testing already being used in cancer care in Europe and elsewhere?
- What can we expect in the future?
- How is the patient community viewing these developments and what are their key asks in respect to achieving improvements?
- How are regulatory and governmental stakeholders responding to the challenges of molecular testing in cancer care, including the growing evidence of hereditary components of cancer?
- How are professions responding to molecular testing?
- What caveats around molecular testing must all stakeholders in cancer care be aware of?
Please click on the video thumbnail to view the related webcast.
